Scroll Back to Top
Labcorp branded background. Blue with dots


Labcorp® Plasma Detect™: 
A WGS-based ctDNA assay for tumor-informed detection of MRD 

Accelerate oncology therapeutic development with fast, high-confidence MRD assessment for global clinical trials

An advanced approach integrating WGS and proprietary machine learning for standardized tumor-informed MRD assessment

Building on a comprehensive portfolio of tissue, liquid biopsy and immune profiling solutions for solid tumors, Labcorp Plasma Detect provides precision monitoring for accelerated clinical trial enrichment strategies and enhanced therapeutic response assessment.

Assess the effectiveness of treatment and identify disease recurrence with an innovative tumor-informed ctDNA molecular residual disease (MRD) assay. This advanced approach integrates whole genome sequencing (WGS) and a proprietary machine learning analysis to identify a high-confidence, patient-specific mutation signature and track it over time—without the need for bespoke panel development.

Scientist looking at a DNA extraction

Robust performance for translational research and clinical trials

Gain more insights with an innovative, sample-sparing approach to tumor-informed MRD assessment 
with high sensitivity and specificity.


0.005% ctDNA content


99.4% specificity


100.0% APA at 0.05% ctDNA level 

8.52% CV in ctDNA levels reported 


Low input requirement (10 ng cfDNA) facilitates higher sample acceptance rate

Labcorp Plasma Detect defines a tumor-informed MRD signature using WGS of tumor DNA, germline DNA from buffy coat and cell-free DNA collected at the landmark time point. These data are analyzed with a proprietary machine learning algorithm to identify thousands of high-confidence, patient-specific somatic tissue variants, creating a signature that can be tracked over time to determine the ctDNA status.

Accelerate time to results with tumor-informed MRD reporting in as few as 14 days

Expedite trial enrichment and evaluation of treatment efficacy with landmark time point results in as few as 14 days and 
longitudinal time point results in as few as 7 days.

Sample accessioning > Processing & Library Prep > Sequencing > Most tumor informed approaches require bespoke panel creation & Validation > Analysis, Report Generation, and Review

The standardized WGS and proprietary machine learning workflow eliminates the need for bespoke panel development and 
manual data curation, expediting delivery of results.

A scalable ctDNA MRD platform to support global clinical development

  • Available for research or investigational use

  • Developed under ISO 13485 design control

  • Performed in a CLIA-certified laboratory

  • Supported by Labcorp’s global laboratory and service network

Labcorp Plasma Detect assay specifications

Test formatTest service for Research Use Only (RUO)
Sequencing workflowWhole genome sequencing (WGS)
AnalysisCell-free DNA (cfDNA) obtained through non-invasive blood draws. The landmark time point undergoes normalization to peripheral bone marrow cells' (PBMCs) DNA and tumor tissue to eliminate germline and non-tumor-specific variants, respectively, from the identified data
Turnaround time (receipt of sample to report)As few as 14 days landmark time point, As few as 7 days longitudinal time point
Specimen typeTumor tissue, buffy coat (PBMCs), plasma
Sample input and collection tube

Tissue: FFPE block or slides (5-10), ≥20% tumor purity 

Plasma and buffy coat: 1 EA Streck OR EDTA (10 mL BCT)

DNA input200 ng (tissue), 50 ng (buffy coat), 10 ng (plasma)
Alterations evaluatedA median of 5000 high confidence single nucleotide variants (SNVs) are identified to create an MRD signature that is tracked longitudinally
Analytical sensitivity0.005% ctDNA content
Analytical specificity99.4%
Precision100.0% APA at 0.05% ctDNA level
8.52% CV in ctDNA levels reported

Enrich patient populations, assess patient prognosis and therapeutic response, and monitor disease recurrence

Empower your clinical trial with a clinically validated MRD assay capable of ctDNA MRD detection months earlier than the current standard of care.

Plasma Detect icon

Gain more high-confidence insights

  • Tumor-informed WGS workflow offers high sensitivity and specificity
  • Low input requirements facilitate higher sample acceptance rates
Icon of a clock with a lightening bolt

Save time with a standardized workflow

  • WGS eliminates bespoke panel development
  • Automated machine learning analysis
Icon of a trending up bar graph

Streamline your development process

  • Developed under design control to expedite assay deployment for clinical trials
  • Backed by Labcorp’s global laboratory network to provide tailored solutions and expertise every step of the way

Stay Connected

Contact Us